These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 16394445

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sti571-induced Stevens-Johnson Syndrome.
    Vidal D, Puig L, Sureda A, Alomar A.
    Br J Haematol; 2002 Oct; 119(1):274-5. PubMed ID: 12358937
    [No Abstract] [Full Text] [Related]

  • 3. Imatinib-induced Stevens-Johnsons syndrome.
    Jha P, Himanshu D, Jain N, Singh AK.
    BMJ Case Rep; 2013 Jan 23; 2013():. PubMed ID: 23349042
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK, King RS.
    Cancer Pract; 2001 Jan 23; 9(5):263-5. PubMed ID: 11879324
    [No Abstract] [Full Text] [Related]

  • 8. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.
    Vora A, Bhutani M, Sharma A, Raina V.
    Ann Oncol; 2002 Nov 23; 13(11):1833-4. PubMed ID: 12419759
    [No Abstract] [Full Text] [Related]

  • 9. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V.
    Ann Oncol; 2004 Feb 23; 15(2):358-9. PubMed ID: 14760137
    [No Abstract] [Full Text] [Related]

  • 10. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P, Larghero J, Raffoux E, Calvo F, Tulliez M, Giraudier S, Rybojad M.
    Br J Haematol; 2003 Mar 23; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec 01; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract] [Full Text] [Related]

  • 13. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
    Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM.
    Indian J Dermatol Venereol Leprol; 2006 Dec 01; 72(1):63-4. PubMed ID: 16481719
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
    Ostro D, Lipton J.
    Leuk Lymphoma; 2007 Jan 01; 48(1):195-6. PubMed ID: 17325868
    [No Abstract] [Full Text] [Related]

  • 16. Precipitation of porphyria cutanea tarda by imatinib mesylate?
    Ho AY, Deacon A, Osborne G, Mufti GJ.
    Br J Haematol; 2003 Apr 01; 121(2):375. PubMed ID: 12694262
    [No Abstract] [Full Text] [Related]

  • 17. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P, Das NK, Sil A, Chakrabarti P.
    J Postgrad Med; 2012 Apr 01; 58(4):331-4. PubMed ID: 23298941
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Gleevec: tailoring to fit.
    May TS.
    Drug Discov Today; 2003 Mar 01; 8(5):188-9. PubMed ID: 12634004
    [No Abstract] [Full Text] [Related]

  • 20. Late onset imatinib-induced Stevens-Johnson syndrome.
    Bois E, Holle LM, Farooq U.
    J Oncol Pharm Pract; 2014 Dec 01; 20(6):476-8. PubMed ID: 24399835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.